A gene expression profile test for the differential diagnosis of ovarian versus endometrial cancers

Oncotarget

Volumn 3, Issue 2, 2012, Pages 212-223

  Lal, Anita ^a   Panos, Rebecca ^a   Marjanovic, Mira ^a   Walker, Michael ^a   Fuentes, Eloisa ^a   Kapp, Daniel S ^b   David Henner, W ^a   Buturovic, Ljubomir J ^a   Halks Miller, Meredith ^a  

^a Pathwork Diagnostics   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Diagnostic test; Endometrial cancer; Gene expression; Ovarian cancer; Tissue of origin

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; DNA MICROARRAY; ENDOMETRIUM TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENETIC SCREENING; GENETICS; HUMAN; METHODOLOGY; MIDDLE AGED; MOLECULAR DIAGNOSIS; OVARY TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENETIC TESTING; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM GRADING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS;

EID: 84863802496     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.450     Document Type: Article

References (37)

1. NCCN Clinical Practice Guidelines in Oncology - Uterine Neoplasms. 2011; Version 2. 2012.
2. NCCN Clinical Practice Guidelines in Oncology - Ovarian Cancer including Fallopian Tube and Primary Peritoneal Cancer. 2011; Version 2.2012.
3. Chang KH, Albarracin C, Luthra R, Wang L, Zheng W, Malpica A, Deavers MT, Silva EG, Liu J. Discordant genetic changes in ovarian and endometrial endometrioid carcinomas: a potential pitfall in molecular diagnosis. Int J Gynecol Cancer. 2006; 16: 178-82.
4. Kurian AW, Balise RR, McGuire V, Whittemore AS. Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol. 2005; 96: 520-30.
5. Levi F, Franceschi S, La Vecchia C, Ruzicka J, Gloor E, Randimbison L. Epidemiologic pathology of ovarian cancer from the Vaud Cancer Registry, Switzerland. Ann Oncol. 1993; 4: 289-94.
6. Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004; 44: 109-15.
7. Mittal K, Soslow R, McCluggage WG. Application of immunohistochemistry to gynecologic pathology. Arch Pathol Lab Med. 2008; 132: 402-23.
8. Mazur MT, Hsueh S, Gersell DJ. Metastases to the female genital tract. Analysis of 325 cases. Cancer. 1984; 53: 1978-84.
9. van Niekerk CC, Bulten J, Vooijs GP, Verbeek AL. The association between primary endometrioid carcinoma of the ovary and synchronous malignancy of the endometrium. Obstet Gynecol Int. 2010; 2010: 465162.
10. Tafe LJ, Garg K, Chew I, Tornos C, Soslow RA. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol. 2010; 23: 781-9.
11. Yaziji H, Gown AM. Immunohistochemical analysis of gynecologic tumors. Int J Gynecol Pathol. 2001; 20: 64-78.
12. Papanastasiou AD, Pampalakis G, Katsaros D, Sotiropoulou G. Netrin-1 overexpression is predictive of ovarian malignancies. Oncotarget. 2011; 2: 363-7.
13. Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol. 2006; 19: 1091-100.
14. Wang Y, van der Zee M, Fodde R, Blok LJ. Wnt/ Beta-catenin and sex hormone signaling in endometrial homeostasis and cancer. Oncotarget. 2010; 1: 674-84.
15. Chudova D, Wilde JI, Wang ET, Wang H, Rabbee N, Egidio CM, Reynolds J, Tom E, Pagan M, Ted Rigl C, Friedman L, Wang CC, Lanman RB, Zeiger M, Kebebew E, Rosai J, et al. Molecular Classification of Thyroid Nodules Using High-Dimensionality Genomic Data. J Clin Endocrinol Metab. 2010; 95: 5296-304.
16. Pillai R, Deeter R, Rigl CT, Nystrom JS, Miller MH, Buturovic L, Henner WD. Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J Mol Diagn. 2011; 13: 48-56.
17. Bloom G, Yang IV, Boulware D, Kwong KY, Coppola D, Eschrich S, Quackenbush J, Yeatman TJ. Multi-platform, multi-site, microarray-based human tumor classification. Am J Pathol. 2004; 164: 9-16.
18. Tothill RW, Kowalczyk A, Rischin D, Bousioutas A, Haviv I, van Laar RK, Waring PM, Zalcberg J, Ward R, Biankin AV, Sutherland RL, Henshall SM, Fong K, Pollack JR, Bowtell DD, Holloway AJ. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res. 2005; 65: 4031-40.
19. Bammler T, Beyer RP, Bhattacharya S, Boorman GA, Boyles A, Bradford BU, Bumgarner RE, Bushel PR, Chaturvedi K, Choi D, Cunningham ML, Deng S, Dressman HK, Fannin RD, Farin FM, Freedman JH, et al. Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods. 2005; 2: 351-6.
20. Dobbin KK, Beer DG, Meyerson M, Yeatman TJ, Gerald WL, Jacobson JW, Conley B, Buetow KH, Heiskanen M, Simon RM, Minna JD, Girard L, Misek DE, Taylor, JM, Hanash S, Naoki K, et al. Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res. 2005; 11: 565-72.
21. Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, Frank BC, Gabrielson E, Garcia JG, Geoghegan J, Germino G, Griffin C, Hilmer SC, Hoffman E, Jedlicka AE, Kawasaki E, Martinez-Murillo F, et al. Multiple-laboratory comparison of microarray platforms. Nat Methods. 2005; 2: 345-50.
22. Acquati F, Monti L, Lualdi M, Fabbri M, Sacco MG, Gribaldo L, Taramelli R. Molecular signature induced by RNASET2, a tumor antagonizing gene, in ovarian cancer cells. Oncotarget. 2011; 2: 477-84.
23. Dunn TA, Fedor H, Isaacs WB, De Marzo AM, Luo J. Genome-wide expression analysis of recently processed formalin-fixed paraffin embedded human prostate tissues. Prostate. 2009; 69: 214-8.
24. Fedorowicz G, Guerrero S, Wu TD, Modrusan Z. Microarray analysis of RNA extracted from formalin-fixed, paraffin-embedded and matched fresh-frozen ovarian adenocarcinomas. BMC Med Genomics. 2009; 2: 23.
25. Penland SK, Keku TO, Torrice C, He X, Krishnamurthy J, Hoadley KA, Woosley JT, Thomas NE, Perou CM, Sandler RS, Sharpless NE. RNA expression analysis of formalin-fixed paraffin-embedded tumors. Lab Invest. 2007; 87: 383-91.
26. Cheng W, Liu J, Yoshida H, Rosen D, Naora H. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med. 2005; 11: 531-7.
27. Li B, Jin H, Yu Y, Gu C, Zhou X, Zhao N, Feng Y. HOXA10 is overexpressed in human ovarian clear cell adenocarcinoma and correlates with poor survival. Int J Gynecol Cancer. 2009; 19: 1347-52.
28. Fiegl H, Windbichler G, Mueller-Holzner E, Goebel G, Lechner M, Jacobs IJ, Widschwendter M. HOXA11 DNA methylation-a novel prognostic biomarker in ovarian cancer. Int J Cancer. 2008; 123: 725-9.
29. Borgono CA, Kishi T, Scorilas A, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, Diamandis EP. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. Clin Cancer Res. 2006; 12: 1487-93.
30. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC, Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005; 99: 267-77.
31. Santin AD, Diamandis EP, Bellone S, Soosaipillai A, Cane S, Palmieri M, Burnett A, Roman JJ, Pecorelli S. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. Clin Cancer Res. 2005; 11: 3320-5.
32. Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15Suppl 3: 274-81.
33. Berry SM. Bayesian adaptive methods for clinical trials, 2010; CRC Press, Boca Raton.
34. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health care evaluation, 2004; Wiley, Chichester; Hoboken, NJ.
35. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993; 39: 561-77.
36. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003; 56: 1129-35.
37. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960; 20: 37-46.